Nanotechnology Now - News Story: U.S. Clinical Trial of VivaGel(TM)

Home > News > U.S. Clinical Trial of VivaGel(TM)

October 25th, 2006

U.S. Clinical Trial of VivaGel(TM)

Abstract:
Starpharma Holdings Limited (ASX: SPL) (OTC: SPHRY) today announced that the U.S. site for the clinical trial of SPL7013 gel (VivaGel(TM)) for prevention of genital herpes has opened for recruitment of volunteers.

Source:
prnewswire

Bookmark:

Related News Press

Nanomedicine

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery: NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery September 13th, 2024

Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024

Nanobody inhibits metastasis of breast tumor cells to lung in mice: “In the present study we describe the development of an inhibitory nanobody directed against an extracellular epitope present in the native V-ATPase c subunit.” August 16th, 2024

Announcements

Nanotechnology: Flexible biosensors with modular design November 8th, 2024

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

Turning up the signal November 8th, 2024

Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024



Premium Products


	Only the news you want to read! Learn More



	Full-service, expert consulting Learn More




	The latest news from around the world, FREE